Researchers also highlighted the significance of TTNT-D as a real-world measure of treatment efficacy, noting it provides ...
August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback